SK280926B6 - Derivát sulfónamidu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje - Google Patents

Derivát sulfónamidu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje Download PDF

Info

Publication number
SK280926B6
SK280926B6 SK363-96A SK36396A SK280926B6 SK 280926 B6 SK280926 B6 SK 280926B6 SK 36396 A SK36396 A SK 36396A SK 280926 B6 SK280926 B6 SK 280926B6
Authority
SK
Slovakia
Prior art keywords
bromo
methyl
benzoxadiazol
benzothiadiazol
chloro
Prior art date
Application number
SK363-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK36396A3 (en
Inventor
Mathias Osswald
Werner Mederski
Dieter Dorsch
Claudia Wilm
Claus J. Schmitges
Maria Christadler
Original Assignee
Merck Patent Gesellschaft Mit Beschr�Nkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gesellschaft Mit Beschr�Nkter Haftung filed Critical Merck Patent Gesellschaft Mit Beschr�Nkter Haftung
Publication of SK36396A3 publication Critical patent/SK36396A3/sk
Publication of SK280926B6 publication Critical patent/SK280926B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK363-96A 1995-03-18 1996-03-18 Derivát sulfónamidu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje SK280926B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19509950A DE19509950A1 (de) 1995-03-18 1995-03-18 Endothelin-Rezeptor-Antagonisten

Publications (2)

Publication Number Publication Date
SK36396A3 SK36396A3 (en) 1997-02-05
SK280926B6 true SK280926B6 (sk) 2000-09-12

Family

ID=7757094

Family Applications (1)

Application Number Title Priority Date Filing Date
SK363-96A SK280926B6 (sk) 1995-03-18 1996-03-18 Derivát sulfónamidu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje

Country Status (26)

Country Link
US (1) US5726194A (ja)
EP (1) EP0733626B1 (ja)
JP (1) JPH08269027A (ja)
KR (1) KR100424045B1 (ja)
CN (1) CN1061652C (ja)
AR (1) AR002284A1 (ja)
AT (1) ATE175666T1 (ja)
AU (1) AU705559B2 (ja)
BR (1) BR9601028A (ja)
CA (1) CA2171934C (ja)
CO (1) CO4700473A1 (ja)
CZ (1) CZ288001B6 (ja)
DE (2) DE19509950A1 (ja)
DK (1) DK0733626T3 (ja)
ES (1) ES2128117T3 (ja)
FI (1) FI960953A (ja)
GR (1) GR3029893T3 (ja)
HU (1) HUP9600663A3 (ja)
NO (1) NO305907B1 (ja)
PL (1) PL184332B1 (ja)
RU (1) RU2168503C2 (ja)
SK (1) SK280926B6 (ja)
TR (1) TR199600212A2 (ja)
TW (1) TW363060B (ja)
UA (1) UA48116C2 (ja)
ZA (1) ZA962144B (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
DE19543639A1 (de) * 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
DE19606980A1 (de) * 1996-02-24 1997-08-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19607096A1 (de) * 1996-02-24 1997-08-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
DE19653037A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19710831A1 (de) * 1997-03-15 1998-09-17 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19712141A1 (de) * 1997-03-22 1998-09-24 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
DE19731571A1 (de) * 1997-07-23 1999-01-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
RU2008136317A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Способы и композиции для лечения диагностикой сердечной недостаточности
AU2007225207A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
CN102924412A (zh) * 2008-01-25 2013-02-13 先正达参股股份有限公司 用作杀虫剂的2-氰基苯基磺酰胺衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
HUP9600663A2 (en) 1997-01-28
CN1061652C (zh) 2001-02-07
CO4700473A1 (es) 1998-12-29
DE59601122D1 (de) 1999-02-25
ES2128117T3 (es) 1999-05-01
HU9600663D0 (en) 1996-05-28
FI960953A (fi) 1996-09-19
TW363060B (en) 1999-07-01
TR199600212A2 (tr) 1997-01-21
NO961072L (no) 1996-09-19
US5726194A (en) 1998-03-10
CZ80096A3 (en) 1996-10-16
CN1141919A (zh) 1997-02-05
CA2171934A1 (en) 1996-09-19
KR100424045B1 (ko) 2004-06-26
GR3029893T3 (en) 1999-07-30
ATE175666T1 (de) 1999-01-15
CZ288001B6 (cs) 2001-03-14
BR9601028A (pt) 1997-12-30
AR002284A1 (es) 1998-03-11
EP0733626B1 (de) 1999-01-13
SK36396A3 (en) 1997-02-05
AU4803996A (en) 1996-09-26
DE19509950A1 (de) 1996-09-19
EP0733626A1 (de) 1996-09-25
DK0733626T3 (da) 1999-08-09
JPH08269027A (ja) 1996-10-15
PL184332B1 (pl) 2002-10-31
PL313280A1 (en) 1996-09-30
FI960953A0 (fi) 1996-02-29
KR960034189A (ko) 1996-10-22
CA2171934C (en) 2007-04-24
AU705559B2 (en) 1999-05-27
NO961072D0 (no) 1996-03-15
UA48116C2 (uk) 2002-08-15
ZA962144B (en) 1996-09-26
HUP9600663A3 (en) 1998-07-28
NO305907B1 (no) 1999-08-16
RU2168503C2 (ru) 2001-06-10

Similar Documents

Publication Publication Date Title
SK280926B6 (sk) Derivát sulfónamidu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
US4101548A (en) 1,2,3-Thiadiazole amides
US4171363A (en) 1,2,3-Thiadiazole process
DE19543639A1 (de) Endothelin-Rezeptor-Antagonisten
CS202052B2 (en) Process for preparing new 4-/2-imidazolin-2-yl-amino/-2,1,3-benzothiadiazoles
SK282703B6 (sk) Benzoxazinónový derivát, jeho použitie a farmaceutický prostriedok na jeho báze
CZ176897A3 (en) Endothelin receptor antagonists, process of their preparation and pharmaceutical composition containing thereof
CZ20012144A3 (cs) Sulfonyloxazolaminy jakoľto terapeuticky účinné látky
SK100296A3 (en) Oxoquinoline carboxylic acid derivative, preparation method therof and pharmaceutical composition containing its
US5821256A (en) Endothelin receptor antagonists
KR100854481B1 (ko) 피페라진일카르보닐퀴놀린 및 ­이소퀴놀린
SK6942002A3 (en) Sulfonyl oxazole amine derivative, process for the preparation thereof, its use and pharmaceutical composition containing same
KR20010087399A (ko) 치환된 벤조[데]이소퀴놀린-1,3-디온
JPH0215547B2 (ja)
CZ2000102A3 (cs) Derivát benzothia(oxa)diazolu a jeho použití jako endothelinových receptorových antagonistů
KR20010022004A (ko) 벤조티아(옥사)디아졸 유도체 및 그의 엔도텔린-수용체길항제로서의 용도
MXPA00000755A (en) Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists
MXPA97004262A (es) Piridazinonas como antagonistas del receptor endotelial
HU201743B (en) Process for producing sulfonamide derivatives with antiarrythmic effect and pharmaceutical compositions comprising same